Sumitomo Pharma Co U/Adr (SMDPY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much. I'm Yutaka Wakemi from the Global Finance. Based on the presentation materials, I will now report on the first quarter results for FY 2025 and the current status of clinical development. Please see page 3. We are pleased to report our Q1 financial results. It is shown on the core IFRS basis. Revenue was 108 billion yen, an increase of 17.3 billion from the same period last year. The main reasons were sales growth of Orgovix and Jamtesa in North America. SG&A expenses and R&D expenses decreased by 8.4 billion. and 4.7 billion yen respectively from the same period last year due to the effects of business structure improvement and reorganization of the regenerative and cell medicine business. Co-operating profit was 20.4 billion yen, an improvement in profit and loss over the same period last year due to increased revenue and decreased expenses. Operating profit was likewise 20.4 billion yen. Profit before taxes were 11.9 billion yen, mainly due to a foreign exchange loss of 6.7 billion yen, resulting from the appreciation of the yen. As a result of the above, net profit attributable to owners of the parent increased to 11.2 billion yen. Although revenues and profits are progressing slightly higher than the annual forecast, the full-year forecast announced at the beginning of the fiscal year remains unchanged, due to a number of uncertain variables at this point in time. The company has also announced a new forecast for the first half of the fiscal year. This will be explained later. Page 4 shows revenue for the North America segment. Sales of Orgovix and Gemtesa grew, resulting in a ¥20.7 billion increase over the same period last year. The year-on-year decrease for Aptium was due to the end of the exclusivity period in May 2025. The segment as a w...